Dechra Pharmaceuticals PLC operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Dechra Pharmaceuticals PLC with three other
pharmaceutical manufacturers in Europe:
sales of £217.10 million [US$300.27 million]
of which 100%
was Antibodies & Related Products),
(£570.50 million [US$789.08 million]
of which 38%
was Interventional Medicine), and
Dottikon ES Holding AG
based in Switzerland
(151.75 million Swiss Francs [US$157.09 million]
of which 89%
was Pharma Products).
Dechra Pharmaceuticals PLC reported sales of £359.28 million (US$496.92 million)
June of 2017.
increase of 45.1%
versus 2016, when the company's sales were £247.56 million.
This was the fourth straight year of sales growth at Dechra Pharmaceuticals PLC.
Sales of Na Pharmaceuticals saw an increase
that was more than double the company's growth rate: sales were up
125.3% in 2017, from
£58.73 million to £132.35 million.